Medy-Tox Inc.
086900.KQ
KOSDAQ85,700.00
KRW
-1,200.00
- -
Medy-Tox Inc.
086900.KQ
(KOSDAQ)
Recent
price
85,700.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Medy-Tox Inc., a South Korean biopharmaceutical leader established in 2000, is engaged in the research, development, and commercialization of advanced biopharmaceuticals and medical aesthetics solutions. Based in Cheongju with a global business hub in Seoul, the company primarily develops botulinum toxin products, hyaluronic acid dermal fillers, and a range of specialized medical devices. Its portfolio of botulinum toxin type A injections includes Neuronox, a lyophilized form extensively used for both aesthetic enhancements, such as improving moderate to severe glabellar lines, and therapeutic applications like addressing foot deformities in pediatric cerebral palsy patients, blepharospasm, and hyperhidrosis. INNOTOX stands out as the world's first liquid-type botulinum toxin, offering convenience with no dilution required and improved safety by excluding animal derivatives. Coretox is another advanced lyophilized product, featuring a pure neurotoxin formulation designed to minimize antibody resistance, used for glabellar wrinkles and upper limb spasticity. The company has also introduced NEWLUX, a next-generation botulinum toxin, gaining traction in international markets, and is developing NivobotulinumtoxinA (MT10109L), a liquid neurotoxin formulation specifically targeting the United States and Canadian markets, with a Biological License Application submitted to the FDA in late 2023 via its North American subsidiary, Luvantas, Inc. In the dermal filler segment, Medy-Tox offers hyaluronic acid-based products such as Neuramis and Potenfill, which are utilized as tissue-recovering biomaterials. Neuramis, a recognized brand, is undergoing expansion with new product lines. The company also develops medical devices, including ComfortDual and Recell Ice for high-frequency tissue coagulation, Neurajet Plus for assisting pharmaceutical injections, Carewave for erectile dysfunction using shockwave therapy, and Careveam for ultraviolet light-based skin ailment treatment. Complementing its aesthetic and therapeutic offerings are dermatological solutions like Neurakin cream for various skin conditions and the derma-cosmetics brand Neuraderm. Medy-Tox achieved record first-quarter revenue in 2025, driven by robust exports and an expanding product range, demonstrating balanced growth across domestic and international markets, particularly in Brazil and the Americas. The company continues to invest significantly in research and development, maintaining an R&D investment ratio of over 15% of sales. It exports its diverse product portfolio to approximately 60 countries globally and is actively pursuing market penetration in the US and Europe. Recent strategic moves include plans to establish a botulinum toxin production facility in Dubai and the approval of NUVIJU (MT921), a proprietary cholic acid-based fat-dissolving injection, with preparations for its global launch underway.